Vito Palombella, PhD

Vito Palombella, Ph.D., serves as the chief scientific officer at Surface Oncology and is leading the drug discovery and translational research efforts at Surface Oncology. Vito brings twenty-five years of scientific leadership and experience advancing first-in-class therapeutic programs, and a successful track record of building drug discovery and development organizations. Prior to joining Surface, he was the executive vice president and chief scientific officer at Infinity Pharmaceuticals, where he was responsible for drug discovery and preclinical development. Previously, he was director of molecular biology and protein chemistry at Syntonix Pharmaceuticals, senior director of cell and molecular biology at Millennium Pharmaceuticals, and also held a number of positions at LeukoSite and ProScript. Vito was involved in the discovery and development of bortezomib (Velcade®), a proteasome inhibitor, and duvelisib (Copiktra®), a PI3K-delta/gamma inhibitor, both for cancer therapy. Vito earned his bachelor’s degree in microbiology from Rutgers University and a master’s degree and doctorate degree in viral oncology and immunology from the New York University Medical Center while working in the laboratory of Jan Vilček, M.D. He was a post-doctoral fellow in Dr. Tom Maniatis’ laboratory at Harvard University.